Evidence map›Paper›PMID 40596466›Full record

ArticleScientific reports2025

Jurkat T-cell lines exhibit marked genomic instability affecting karyotype, mutational profile, gene expression, immunophenotype and function.

Andrew Wilson, Nathaniel Dasyam, Felix O'Hagan, Dianna Farrell, Claire Turner, Anne Jay, Alfonso Schmidt, Rachel Beddow, Tina Lillis, Tom Chin and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Combined exposure to emergingFrontiers in toxicology · 2026
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Andrew WilsonDepartment of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.
Nathaniel DasyamCancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
Felix O'HaganCancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
Dianna FarrellWellington Regional Genetics Laboratory, Te Whatu Ora Health New Zealand, Capital, Coast, and Hutt Valley, Wellington, New Zealand.
Claire TurnerWellington Regional Genetics Laboratory, Te Whatu Ora Health New Zealand, Capital, Coast, and Hutt Valley, Wellington, New Zealand.
Anne JayWellington Regional Genetics Laboratory, Te Whatu Ora Health New Zealand, Capital, Coast, and Hutt Valley, Wellington, New Zealand.
Alfonso SchmidtHugh Green Technology Centre, Malaghan Institute of Medical Research, Wellington, New Zealand.
Rachel BeddowWellington Regional Genetics Laboratory, Te Whatu Ora Health New Zealand, Capital, Coast, and Hutt Valley, Wellington, New Zealand.
Tina LillisWellington Regional Genetics Laboratory, Te Whatu Ora Health New Zealand, Capital, Coast, and Hutt Valley, Wellington, New Zealand.
Tom ChinWellington Regional Genetics Laboratory, Te Whatu Ora Health New Zealand, Capital, Coast, and Hutt Valley, Wellington, New Zealand.
Rachel PerretCancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
Michelle McCulley *Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.
Robert Weinkove *Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand. rweinkove@malaghan.org.nz.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Jurkat cell line, derived from a case of T-cell lymphoblastic leukaemia, is widely employed as a model T-cell for biomedical research, including for the preclinical characterisation of cellular therapies such as chimeric antigen receptor T-cells. Here, we characterised genomic, transcriptomic, and functional features of Jurkat clone E6-1 cells from three different laboratories and compared these with Jurkat E6-1 cells from the American Type Culture Collection (ATCC). We identified marked karyotypic heterogeneity both between and within Jurkat E6-1 populations, confirmed through chromosomal microarray. Whole exome sequencing of each cell population revealed both shared and unique mutational profiles, and transcriptomic profiles varied markedly between Jurkat E6-1 cell populations. Finally, the Jurkat E6-1 cell populations exhibited substantial variations in immunophenotype and cytokine production, which were consistent with the genotypic and transcriptomic changes observed. In summary, we identify substantial genomic heterogeneity both between and within Jurkat E6-1 cell populations, highlighting the genomic instability of this line. These genomic changes were associated with differences in protein expression and cytokine production that may affect functional assays. Our findings highlight the importance of monitoring cell passage number, characterising cell lines, and replacing cell line stocks to assure the accuracy, reproducibility, and translatability of assays employing Jurkat E6-1 cells.

Indexed as

Genomic InstabilityKaryotypeMutationCytokinesGene Expression ProfilingHumansImmunophenotypingJurkat CellsKaryotypingTranscriptomeCytokines

Identifiers

PMID40596466
PMCPMC12214745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.